Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the pricing of an underwritten public offering of 3,240,741 American Depositary Shares, each representing one ordinary share, at a price to the public of $54.00 per ADS, for gross proceeds of $175.0 million.
October 13, 2021
· 3 min read